微波消融联合TKI分子靶向治疗非小细胞肺癌的研究现状

Research status of microwave ablation combined with TKI molecular targeted therapy for non⁃small cell lung cancer

肺癌作为高发且致死率极高的恶性肿瘤,尽管通过手术、化放疗、免疫治疗、分子靶向等在临床上取得显著的疗效,但患者的5年生存率仍然不尽人意,微波消融作为一种较新的局部治疗方法,以其微创、副作用小、能够延长生存期并保留器官完整性的优势,正逐渐成为肺癌治疗领域的焦点。该文旨在总结微波消融联合奥希替尼的协同治疗效果,分析其临床效益,并对微波消融与分子靶向药物联合治疗前景进行展望。

As a malignant tumor with high incidence and high mortality,lung cancer poses a serious threat to human health.Although surgery,radiotherapy,chemotherapy,immunotherapy and molecular targeting have achieved certain clinical results,the five⁃year survival rate of patients is still unsatisfactory.As a relatively new local treatment,microwave ablation is becoming a focus in the field of lung cancer treatment for its advantages of minimally invasive,low side effects,prolonged survival and preservation of organ integrity.This paper aims to summarize the synergic therapeutic effect of microwave ablation combined with Osimertinib,to analyze its clinical benefits,especially the influence of combined use of Osimertinib,and to forecast the potential of microwave ablation technology combined with molecular targeted drugs in the future.